Postpartum hemorrhage

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Postpartum hemorrhage
Classification and external resources
ICD-10 O72
ICD-9 666
MeSH D006473

Hemorrhage after delivery, or postpartum hemorrhage, is the loss of greater than 500 ml of blood following vaginal delivery, or 1000 ml of blood following cesarean section. It is the most common cause of perinatal maternal death in the developed world and is a major cause of maternal morbidity worldwide.[1]

Contents

Causes [edit]

Causes of postpartum hemorrhage and their incidence[1]
Cause Incidence
Uterine atony 70%
Trauma 20%
Retained tissue 10%
Coagulopathy 1%

Causes of postpartum hemorrhage are uterine atony, trauma, retained placenta, and coagulopathy, commonly referred to as the "four Ts":[1]

  • Tone: uterine atony is the inability of the uterus to contract and may lead to continuous bleeding. Retained placental tissue and infection may contribute to uterine atony.
  • Trauma: trauma from the delivery may tear tissue and vessels leading to significant postpartum bleeding.
  • Tissue: retention of tissue from the placenta or fetus may lead to bleeding.
  • Thrombin: a bleeding disorder occurs when there is a failure of clotting, such as with diseases known as coagulopathies.

Management [edit]

Medication [edit]

Intravenous oxytocin is the drug of choice for postpartum hemorrhage. Misoprostol may also be effective if oxytocin is not available.[2]

Protocol [edit]

A detailed stepwise management protocol has been introduced by the California Maternity Quality Care Collaborative.[3] It describes 4 stages of obstetrical hemorrhage after a delivery and its application reduces maternal mortality.[4]

A Cochrane review suggests that active management (use of uterotonic drugs, cord clamping and controlled cord traction) of the third stage of labour significantly reduces severe maternal bleeding and anemia compared to expectant management.[5] However, the review also found that active management increased the mother's blood pressure, afterpains, nausea, vomiting, and use of drugs for pain relief. In the active management group more women returned to hospital with bleeding after discharge, and there was also a reduction in birthweight due to infants having a lower blood volume. Another Cochrane database study,[6] focusing specifically on the timing of the administration of the uterotonic drug oxytocin as part of the active management of the third stage of labour, suggested that administering the drug before the expulsion of the placenta did not have any significant influence on the incidence of postpartum hemorrhage when compared to administering the drug after the expulsion of the placenta.

See also [edit]

References [edit]

  1. ^ a b c Anderson JM, Etches D (March 2007). "Prevention and management of postpartum hemorrhage". American Family Physician 75 (6): 875–82. PMID 17390600. 
  2. ^ "Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labour: a double-blind, randomised, non-inferiority trial : The Lancet". 
  3. ^ [1] CMQCC guidelines, accessed August 10, 2009
  4. ^ Barbieri RL. "Planning reduces the risk of maternal death. This tool helps". OBG Management (2009) 21 (8):8-10. 
  5. ^ Begley, C; Gyte G, Devane D, McGuire W, Weeks A (2011). "Active versus expectant management for women in the third stage of labour". Cochrane Database of Systematic Reviews (11). doi:10.1002/14651858.CD007412.pub3. 
  6. ^ Soltani H, Hutchon DR, Poulose TA. (2010). "Timing of prophylactic uterotonics for the third stage of labour after vaginal birth". In Soltani, Hora. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD006173.pub2. 

External links [edit]